Q4 2018 Investor Presentation

Key Financial Results * Revenue Gross margin Non-GAAP operating profit* Non-GAAP net income* Non-GAAP EPS* Cash flow from operations Free cash flow Q4 2018 FY 2018 $623.6M $2,340.2M +12% (+10% CC) +13% (+10% CC) 58.1% 58.2% $166.0M $606.6M +19% $136.3M +24% +19% $507.8M +27% $0.95 $3.53 +23% +25% $129.4M $505.0M $111.8M $442.4M ResMed adjusts for the impact of the amortization of acquired intangibles, impact of U.S. tax reform, and restructuring expenses, from their evaluation of ongoing operations and believes investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. © 2018 ResMed | Q4 2018 Investor Presentation | 31 ResMed

View entire presentation